Federal Scrutiny Forces Pharmacies to Rethink Business Strategy

2026-10-23 economy

Washington, Friday, 23 October 2026.
Strict federal rules now strip prescription drug pricing from manager fees, forcing pharmacies to audit operations and secure new contracts to prevent sudden revenue losses.

Legislative Shifts and Federal Oversight

Earlier in 2026, President Trump and Congress enacted the Consolidated Appropriations Act (CAA), representing the most significant changes to the pharmacy benefit manager (PBM) industry in history [2]. This landmark legislation mandates 100% rebate pass-through for employers and establishes new Medicare guidelines for transparency [2]. On October 20, 2026, the Centers for Medicare & Medicaid Services (CMS) published a proposed rule to implement sections of the CAA, specifically targeting Medicare Part PBM compensation structures [6]. The proposed rule restricts Medicare Part D PBM compensation to flat, fair-market-value service fees detached from drug prices, rebates, or formulary placement [5]. Full implementation of these federal protections, including mandates for reasonable contract terms, is scheduled for 2028 or 2029 [1].

Market Concentration and Pharmacy Risks

Despite legislative progress, three major PBM conglomerates—CVS Caremark, Express Scripts, and OptumRx—control approximately 80% of US prescription volume [3]. Legal experts warn that losing a single contract with these entities can lead to aggressive audits, payment withholdings, and retroactive clawbacks [1]. Research indicates that over 50% of American adults rely on prescription coverage to manage chronic conditions like hypertension and diabetes [1]. Consequently, loss of network access directly correlates to reduced patient adherence and increased emergency room utilization [1]. Independent pharmacies are advised to conduct quarterly internal self-audits to reconcile drug inventory and review bona fide service fee language [1].

State Enforcement Challenges

While states have increasingly passed legislation to regulate PBMs since the 2020 Supreme Court Rutledge decision, enforcement mechanisms often remain insufficient [4]. The 10th Circuit Court of Appeals decision in PCMA v. Mulready (2023) limits the scope of state laws by establishing that ERISA preempts state laws dictating PBM network structure and benefit administration [4]. Medicare Part D claims remain under exclusive federal jurisdiction, confirming that state laws attempting to regulate Part D claims are preempted [4]. Attorneys advocate for a private right of action as the most effective enforcement tool, allowing pharmacies to pursue relief directly rather than relying on state agencies [4]. This approach is viewed as cost-effective and avoids the need for state tax dollars to fund agency-led enforcement efforts [4].

Legislative Outlook and Strategic Adjustments

The upcoming US midterm elections in November 2026 are identified as a critical window to break the legislative impasse and potentially enable further federal PBM reform [3]. A Democratic-controlled Congress would likely prioritize PBM regulation, whereas continued Republican control makes major federal legislation unlikely [3]. Industry stakeholders are monitoring these developments closely, with a professional panel discussion regarding PBM regulatory shifts scheduled for December 15, 2026 [8]. Compliant pharmacies in good standing are best positioned to leverage statutory protections and challenge improper network actions without fear of retaliation [1]. As the industry awaits further clarity, the balance between federal oversight and market competition remains a pivotal economic factor for 2027.

Sources

Pharmacy Benefit Managers Healthcare Regulation